M. Ramamoorth and A. Narvekar, Non viral vectors in gene therapydan overview, J Clin Diagn Res, vol.9, issue.1, pp.1-06, 2015.

C. Bloquel, J. L. Bourges, E. Touchard, M. Berdugo, D. Benezra et al., Nonviral ocular gene therapy: potential ocular therapeutic avenues, Adv Drug Deliv Rev, vol.58, issue.11, pp.1224-1242, 2006.

R. R. Ali, A. Auricchio, and A. J. Smith, The future looks brighter after 25 years of retinal gene therapy, Hum Gene Ther, vol.28, pp.982-987, 2017.

S. E. Boye, S. L. Boye, A. S. Lewin, and W. W. Hauswirth, A comprehensive review of retinal gene therapy, Mol Ther, vol.21, issue.3, pp.509-519, 2013.

C. Sch?-on, M. Biel, and S. Michalakis, Retinal gene delivery by adeno-associated virus (AAV) vectors: strategies and applications, Eur J Pharm Biopharm, vol.95, pp.343-352, 2015.

I. Trapani, A. Puppo, and A. Auricchio, Vector platforms for gene therapy of inherited retinopathies, Prog Retin Eye Res, vol.43, pp.108-128, 2014.

S. Grosse, M. Penaud-budloo, and A. K. Herrmann, Relevance of assemblyactivating protein for Adeno-associated virus vector production and capsid protein stability in mammalian and insect cells, J Virol, vol.91, pp.1198-01217, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01785930

F. Sonntag, K. Schmidt, and J. A. Kleinschmidt, A viral assembly factor promotes AAV2 capsid formation in the nucleolus, Proc Natl Acad Sci U S A, vol.107, issue.22, pp.10220-10225, 2010.

A. Bennett, S. Patel, and M. Mietzsch, Thermal stability as a determinant of AAV serotype identity, Mol Ther Methods Clin Dev, vol.6, pp.171-182, 2017.

S. Pacouret, M. Bouzelha, and R. Shelke, AAV-ID: a rapid and robust assay for batch-to-batch consistency evaluation of AAV preparations, Mol Ther, vol.25, issue.6, pp.1375-1386, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01798869

F. H. Niesen, H. Berglund, and M. Vedadi, The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability, Nat Protoc, vol.2, issue.9, pp.2212-2221, 2007.

A. Carreira, M. Menendez, J. Reguera, J. M. Almendral, and M. G. Mateu, In vitro disassembly of a parvovirus capsid and effect on capsid stability of heterologous peptide insertions in surface loops, J Biol Chem, vol.279, issue.8, pp.6517-6525, 2004.

E. Becirovic, S. Bohm, and O. N. Nguyen, AAV vectors for FRET-based analysis of protein-protein interactions in photoreceptor outer segments, Front Neurosci, vol.10, p.356, 2016.

C. Sch?-on, E. Becirovic, M. Biel, and S. Michalakis, Design and development of AAVbased gene supplementation therapies for achromatopsia and retinitis pigmentosa, Methods Mol Biol, vol.1715, pp.33-46, 2018.

M. Penaud-budloo, E. Lecomte, and A. Guy-duche, Accurate identification and quantification of DNA species by next-generation sequencing in adenoassociated viral vectors produced in insect cells, Hum Gene Ther Methods, vol.28, issue.3, pp.148-162, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01607265

E. Ayuso, F. Mingozzi, and J. Montane, High AAV vector purity results in serotype-and tissue-independent enhancement of transduction efficiency, Gene Ther, vol.17, pp.503-510, 2010.

M. Lock, S. Mcgorray, and A. Auricchio, Characterization of a recombinant adeno-associated virus type 2 reference standard material, Hum Gene Ther, vol.21, issue.10, pp.1273-1285, 2010.

D. Grimm, A. Kern, M. Pawlita, F. K. Ferrari, R. J. Samulski et al., Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2, Gene Ther, vol.6, issue.7, pp.1322-1330, 1999.

S. D'costa, V. Blouin, and F. Broucque, Practical utilization of recombinant AAV vector reference standards: focus on vector genomes titration by free ITR qPCR, Mol Ther Methods Clin Dev, vol.5, p.16019, 2016.

H. Svilenov and G. Winter, The ReFOLD assay for protein formulation studies and prediction of protein aggregation during long-term storage, Eur J Pharm Biopharm, vol.137, pp.131-139, 2019.

N. Breitsprecher, A. Hawe, and T. Menzen, Thermal Unfolding of Anti-bodies Comparison of NanoDSF and MDSC for Thermal Stability Assessment During Biopharmaceutical Formulation Development, Nano-TemperTechnol GmbH, 2016.

V. Rayaprolu, S. Kruse, and R. Kant, Comparative analysis of adeno-associated virus capsid stability and dynamics, J Virol, vol.87, issue.24, pp.13150-13160, 2013.

N. G. Rumachik, S. A. Malaker, and N. Poweleit, Methods matterdstandard production platforms for recombinant AAV can produce chemically and functionally distinct vectors, p.640169, 2019.

J. F. Wright, Product-related impurities in clinical-grade recombinant AAV vectors: characterization and risk assessment, Biomedicines, vol.2, issue.1, pp.80-97, 2014.

G. A. Rodrigues, E. Shalaev, T. K. Karami, J. Cunningham, N. Slater et al., Pharmaceutical development of AAV-based gene therapy products for the eye, Pharm Res, vol.36, issue.2, p.29, 2018.

T. Menzen and W. Friess, High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants, J Pharm Sci, vol.102, issue.2, pp.415-428, 2013.

R. Wanner, D. Breitsprecher, S. Duhr, P. Baaske, and G. Winter, Thermo-optical protein characterization for straightforward preformulation development, J Pharm Sci, vol.106, issue.10, pp.2955-2958, 2017.

D. B. Howard and B. K. Harvey, Assaying the stability and inactivation of AAV serotype 1 vectors, Hum Gene Ther Methods, vol.28, issue.1, pp.39-48, 2017.

J. F. Wright, T. Le, and J. Prado, Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation, Mol Ther, vol.12, issue.1, pp.171-178, 2005.

T. A. Khan, H. C. Mahler, and R. S. Kishore, Key interactions of surfactants in therapeutic protein formulations: a review, Eur J Pharm Biopharm, vol.97, pp.60-67, 2015.

N. B. Bam, J. L. Cleland, and J. Yang, Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions, J Pharm Sci, vol.87, issue.12, pp.1554-1559, 1998.

J. F. Wright, AAV empty capsids: for better or for worse?, Mol Ther, vol.22, issue.1, pp.1-2, 2014.

G. Qu, J. Bahr-davidson, and J. Prado, Separation of adeno-associated virus type 2 empty particles from genome containing vectors by anion-exchange column chromatography, J Virol Methods, vol.140, issue.1-2, pp.183-192, 2007.

M. Urabe, K. Q. Xin, and Y. Obara, Removal of empty capsids from type 1 adeno-associated virus vector stocks by anion-exchange chromatography potentiates transgene expression, Mol Ther, vol.13, issue.4, pp.823-828, 2006.

S. A. Nass, M. A. Mattingly, and D. A. Woodcock, Universal method for the purification of recombinant AAV vectors of differing serotypes, Mol Ther Methods Clin Dev, vol.9, pp.33-46, 2018.

B. Burnham, S. Nass, and E. Kong, Analytical ultracentrifugation as an approach to characterize recombinant adeno-associated viral vectors, Hum Gene Ther Methods, vol.26, issue.6, pp.228-242, 2015.

J. C. Grieger, V. W. Choi, and R. J. Samulski, Production and characterization of adenoassociated viral vectors, Nat Protoc, vol.1, issue.3, pp.1412-1428, 2006.